RobertBruceMontgomeryMD

Oncology • Seattle, WA

Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Montgomery is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Montgomery's full profile

Already have an account?

Office
1959 Ne Pacific St
Box 356158
Seattle, WA 98195
Phone+1 206-598-0860

Clinical Expertise

General medical oncology, Hematologic oncology, Urethral cancer

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1990 - 1993
Brigham and Women's HospitalResidency, Internal Medicine, 1987 - 1990
Duke University School of MedicineClass of 1987

Certifications & Licensure

WA State Medical License 1990 - 2025

Clinical Trials

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 2
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer Start of enrollment: 2009 Aug 01
Recruiting
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Completed
Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2013 May 01
Completed
Not Applicable
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1, Phase 2
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers Start of enrollment: 2021 Aug 31
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss Start of enrollment: 2024 May 31
Recruiting
Phase 2
Roles: Contact
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer Start of enrollment: 2019 Oct 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

776 citations
Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia
Proceedings of the National Academy of Sciences of the United States of America. 2019-06-04
15 citations
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
Navonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, Ilsa Coleman, Gavin Ha
JCI Insight. 2021-12-08
803 citations
Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro
Cell. 2015-05-21